Putnam Investments LLC lifted its stake in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 10.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 67,928 shares of the medical technology company’s stock after buying an additional 6,441 shares during the period. Putnam Investments LLC’s holdings in Hill-Rom were worth $7,107,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. BB&T Securities LLC purchased a new position in shares of Hill-Rom during the second quarter valued at approximately $322,000. Parametric Portfolio Associates LLC boosted its position in shares of Hill-Rom by 10.5% during the first quarter. Parametric Portfolio Associates LLC now owns 149,080 shares of the medical technology company’s stock valued at $15,782,000 after buying an additional 14,223 shares during the last quarter. Campbell & CO Investment Adviser LLC boosted its position in shares of Hill-Rom by 142.2% during the second quarter. Campbell & CO Investment Adviser LLC now owns 5,812 shares of the medical technology company’s stock valued at $608,000 after buying an additional 3,412 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Hill-Rom by 40.8% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,460 shares of the medical technology company’s stock valued at $676,000 after buying an additional 1,873 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. purchased a new position in shares of Hill-Rom during the second quarter valued at approximately $1,350,000. 82.67% of the stock is currently owned by institutional investors.
Several research analysts have weighed in on the company. KeyCorp boosted their price objective on Hill-Rom from $114.00 to $125.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Zacks Investment Research raised Hill-Rom from a “hold” rating to a “buy” rating and set a $103.00 price objective on the stock in a research report on Thursday, June 6th. ValuEngine cut Hill-Rom from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Barclays boosted their price objective on Hill-Rom from $108.00 to $116.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $125.00 price objective on shares of Hill-Rom in a research report on Tuesday, August 6th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $112.43.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings data on Friday, August 2nd. The medical technology company reported $1.23 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.21 by $0.02. Hill-Rom had a return on equity of 21.26% and a net margin of 7.45%. The business had revenue of $726.80 million for the quarter, compared to analysts’ expectations of $718.08 million. During the same quarter in the previous year, the firm earned $1.15 earnings per share. The business’s revenue was up 2.6% on a year-over-year basis. As a group, equities analysts forecast that Hill-Rom Holdings, Inc. will post 5.05 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Friday, September 20th will be paid a $0.21 dividend. The ex-dividend date is Thursday, September 19th. This represents a $0.84 annualized dividend and a dividend yield of 0.80%. Hill-Rom’s payout ratio is presently 17.68%.
In other Hill-Rom news, SVP Deborah Rasin sold 5,500 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $103.00, for a total value of $566,500.00. Following the sale, the senior vice president now directly owns 20,939 shares in the company, valued at $2,156,717. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Paul Sherwood Johnson sold 6,470 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $104.26, for a total value of $674,562.20. Following the completion of the sale, the senior vice president now owns 8,215 shares in the company, valued at $856,495.90. The disclosure for this sale can be found here. Insiders own 0.73% of the company’s stock.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Further Reading: What defines an oversold asset?
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.